Pricing Log in Create free account

4D Molecular Therapeutics, Inc. (FDMT) vs Immix Biopharma, Inc. (IMMX)

4D Molecular Therapeutics, Inc. and Immix Biopharma, Inc. are both Biotechnology companies. 4D Molecular Therapeutics, Inc. and Immix Biopharma, Inc. are of similar size ($719.6M and $711.0M). Immix Biopharma, Inc. has the higher net margin (0.00% vs −194.7%) and the higher return on invested capital (0.00% vs −186.9%). Across the 13 metrics below, Immix Biopharma, Inc. leads on 10 and 4D Molecular Therapeutics, Inc. on 3.

Valuation

Metric FDMT IMMX Biotechnology median
P/E n/m n/m 8.50
P/S 9.27 n/m 9.71
P/B 2.09 2.22 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 5.56 n/m 9.21
Earnings yield (21.66%) (11.03%) (33.15%)
Free cash flow yield (18.28%) (7.68%) (25.50%)

Profitability

Metric FDMT IMMX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (214.24%) 0.00% 0.00%
Net margin (194.74%) 0.00% 0.00%
Free cash flow margin (169.51%) 0.00% 0.00%
Return on equity (43.25%) (34.18%) (56.36%)
Return on assets (37.09%) (31.34%) (48.04%)
Return on invested capital (186.91%) 0.00% 0.00%

Growth

Metric FDMT IMMX Biotechnology median
Revenue growth (TTM) 278,712.12% — 6.02%
EPS growth (last fiscal year) 18.79% (17.11%) 30.26%
Revenue growth, 5-year CAGR 44.32% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FDMT IMMX Biotechnology median
Debt to equity 0.05 0.00 0.00
Current ratio 8.03 25.13 4.72
Net debt to EBITDA 2.52 3.39 0.96

Dividend

Metric FDMT IMMX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FDMT IMMX Biotechnology median
Market cap 710.99m 719.59m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack